CN1160061C - Core tablet for controlled release of gliclazide after oral administration - Google Patents

Core tablet for controlled release of gliclazide after oral administration Download PDF

Info

Publication number
CN1160061C
CN1160061C CNB998159603A CN99815960A CN1160061C CN 1160061 C CN1160061 C CN 1160061C CN B998159603 A CNB998159603 A CN B998159603A CN 99815960 A CN99815960 A CN 99815960A CN 1160061 C CN1160061 C CN 1160061C
Authority
CN
China
Prior art keywords
gliclazide
matrix tablet
tablet
gross weight
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998159603A
Other languages
Chinese (zh)
Other versions
CN1342068A (en
Inventor
B�������ص°�������
B·修伊特德巴罗切兹
P·伍斯里奇
L·马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9541429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1160061(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of CN1342068A publication Critical patent/CN1342068A/en
Application granted granted Critical
Publication of CN1160061C publication Critical patent/CN1160061C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a matrix tablet for the prolonged release of gliclazide which ensures continuous and consistent release of the active ingredient after administration by the oral route, the release being insensitive to variations in the pH of the dissolution medium.

Description

After oral administration, prolong the matrix tablet that discharges gliclazide
The present invention relates to the matrix tablet of slow release gliclazide, this release is insensitive to the variation of the pH of dissolve medium, and can guarantee rule and successive blood drug level after the dosage form oral route absorbs
Gliclazide, the chemical compound of chemical formula (I):
It is a kind of sulphur carbamide compound that just has the anti-diabetic performance at the dosage of common administration of human.
The tablet form of gliclazide by containing 80mg dosage is by oral administration so far.Conventional average recipe quantity is two of administrations every day, and administration at twice, but depend on the seriousness of diabetes, administration every day can from 1 to 4, divide administration several times.
But a project of the present invention is the peroral dosage form of acquisition a kind of every day of single-dose.On the one hand, this is easy to use for patient, on the other hand, and the treatment of its better fit.
But another purpose of the present invention is this peroral dosage form slow release.Really, the dosage form that discharges immediately in some patients causes blood high concentration a middle or short term.Slow release formulation can be avoided peak value such in the blood, and obtains stable concentration in blood of human body.This may reduce the undesirable effect that is caused by " peak effect ", and this effect is accompanied by the water electrolysis relevant with active component concentration change in blood plasma-and the disorder of metabolism-type.
Main purpose of the present invention is to obtain a kind of peroral dosage form, and wherein the release of active component is may command and reproducible.In fact, the dissolving of the active component of current dosage form alters a great deal with pH.This character, relevant with gliclazide self, cause the absorption problem of active component.The dissolubility of active component (is enclosed) as shown in Figure 1 according to the phenomenon that pH changes.Dissolubility is very little at acid ph value, improves when pH raises.
Thereby for this active component, developing a kind of new made gliclazide, to discharge the gliclazide dosage form that is independent of dissolve medium pH be important.
More particularly, the invention describes a kind of hydrophilic skeleton, but its by oral route administration, and prolongation and sustained release active component-gliclazide, and do not have the dissolution in vitro kinetics of the pH influence of described skeleton.
The gliclazide extended release dosage form that is used for treating diabetes can provide more stable plasma concentration and less C Max-C MinChange.Rate of release is reproducible, and is associated with observed haemoconcentration after the administration.
Among the mechanism that is used to control soluble active component diffusion, selects a most important mechanism, it is an active component hydrophilic polymer contacts also swelling with lysate (external) or stomach-intestinal juice (in the body) after, by the diffusion of gel.
Many polymer that are suitable for preparing this gel were once described.Main polymer is a cellulosic cpd, cellulose ether particularly, and for example hydroxypropyl cellulose, hydroxyethyl-cellulose, methylcellulose and hydroxypropyl emthylcellulose, and in the extensive stock grade of those ethers, those of viscosity higher.The system that should be noted that description does not have obtain 0 grade theoretic probability in the release dynamics equation.
Be used for the preparation technology of this matrix tablet at present or direct compression, perhaps wet granulation after mixing various excipient and active component.
The gliclazide matrix tablet that the present invention describes has made up at least a cellulosic polymer chemical compound and glucose syrup (corn starch hydrolyzate) with a kind of new method, makes the release of the preferred active component that prolongs and control become possibility.
This controlled release surpass eight hours during in be rectilinear, between 4 and 6 hours, discharged 50% of gliclazide total amount.In addition, according to matrix tablet energy slow release gliclazide of the present invention, after the oral route single-dose of the gliclazide sheet that contains 30mg dosage 12 hours at the most, produce 400 to 700ng/ml human body blood drug level, and after gliclazide sheet administration every day that contains 30mg dosage, concentration is 250 to 1000ng/ml.
Character and seriousness according to age of patient, body weight, diabetes can change unit dose.For the treatment of every day, the common scope of single-dose is 30 to 120mg.In the matrix tablet percent of gliclazide be sheet heavy 12 to 40%.According to the useful embodiment of the present invention, described gliclazide that contains 60mg dosage.Particularly preferred embodiment of the present invention provides the gliclazide sheet that contains 30 dosage.In the useful embodiment of those the present invention, for single-dose every day, scope is 30 to 120mg unit dose, with contain 1 to 4 of 30mg dosage or contain the absorption of 1 to 2 of 60mg dosage corresponding.On the one hand but the matrix tablet described of applicant has the peroral dosage form of single-dose every day, on the other hand, astoundingly and especially valuably, the active component content in reducing every and do not change and change the plasma concentration of gliclazide.The existing 80mg gliclazide dosage that contains of this so far preparation.
The particular combinations of above-claimed cpd astoundingly, makes the dissolution in vitro kinetics of described skeleton not be subjected to the influence of pH, although the dissolubility of active component is with same pH change.This point is by Fig. 2 introduction (enclosing), and the stomach frame that its shows preparation is that 6.2 to 7.4 pH change is insensitive for the scope that occurs in the enteral environment.Thereby, correspond in the scope of pH6 to 8 of the ascending curve that Fig. 1 (enclosing) shows, it is identical can observing the release profiles of active component between 0 and 12 hour, irrelevant with the pH of the dissolve medium of the matrix tablet that contains described active component.
Thereby, characteristics combination by at least a cellulosic polymer chemical compound and glucose syrup, the applicant has created a kind of hydrophilic skeleton, it is innovated at its composition and its function aspects, because, particularly, it can discharge contained active component gliclazide in the mode that prolongs and control, and irrelevant with the pH of dissolve medium.
The cellulosic polymer chemical compound that uses in the hydrophilic skeleton is full-bodied cellulose ether.Valuably, cellulose ether is a hydroxypropyl emthylcellulose, the combination of the hydroxypropyl emthylcellulose of preferred two kinds of different viscosities.Another chemical compound is a glucose syrup in the described backbone composition, and valuably, adopts maltodextrin, and it is to have the tire glucose syrup of (ED) of 1 to 20 D-glucose.On the one hand this compound compositions of two types can obtain the active component release profiles pH of dissolve medium is changed insensitive preparation, on the other hand, has obtained the release dynamics of good control.The percent of cellulosic polymer chemical compound be sheet heavy 10 to 40%, according to useful especially embodiment, be sheet heavy 16 to 26%.The percent of glucose syrup be sheet heavy 2 to 20%, preferred sheet heavy 4 to 10%.
Also can add various excipient to improve preparation.In the diluent that routine is used, preferably adopt dicalcium phosphate dihydrate, the granule tabletting that it can improve particulate flowability and be improved.In addition, dicalcium phosphate dihydrate can slow down dissolution kinetics, and this feature makes and can adopt the release profiles of the HYDROXY PROPYL METHYLCELLULOSE control active component of a small amount of.The percent of dicalcium phosphate dihydrate be sheet heavy 35 to 75%, preferred sheet heavy 45 to 60%.In the lubricant, mentioned magnesium stearate, stearic acid, Gan You behenic acid ester and sodium benzoate, in fluidizer, preferably adopted colloidal silica anhydrous by example.
The present invention also relates to the preparation of matrix tablet.By mixed active composition, glucose syrup and dicalcium phosphate dihydrate, then wet mix is carried out wet granulation.The first step produces the hydrophilic environments that promotes its excellent dissolution around active component, and stable unit dose is provided as far as possible.In second step, the granule that more than obtains mixes with cellulose ether.If wish that cellulose ether can directly be granulated with active component in the first step.Then by adding silica sol and magnesium stearate lubrication mixture.The mixture of the final lubricated mistake of tabletting then.
The following example is introduced the present invention, but is not to limit the present invention by any way.
The preparation of the extended release sheet of oral administration is carried out according to following production technology:
Steps A:
The mixture of gliclazide, maltodextrin and dicalcium phosphate dihydrate is with the pure water wet mix.The moist wood of gained is then granulated, dry and classification subsequently, obtains having the granule that can well fill the physical features of quick tablet machine mould.
Step B:
The granule that steps A obtains mixes with hydroxypropyl emthylcellulose.
Step C:
Lubricate the mixture that step B obtains with silica sol and magnesium stearate.
Step D:
The lubricated mixture that adopts rotary tablet machine tabletting step C to obtain is with obtain to have about 6 to the 10daN hardness sheet of (measuring by the diameter crushing).
Embodiment 1:
Embodiment 1 shows that maltodextrin is to the release in vitro effect of kinetics.Maltodextrin every content 7.5 is to 15mg, thus form sheet heavy 4 to 10%.It is stable that the amount of hydroxypropyl emthylcellulose keeps, and the amount of regulating the diluent dicalcium phosphate dihydrate is to obtain to have the sheet of 160mg stable weight.Be prepared according to steps A to the program that D describes.
Table 1: unit preparation (every of mg) and the feature of tablet
Batch
Component LP1 LP2
Gliclazide 30 30
Dicalcium phosphate dihydrate 87.4 79.9
Maltodextrin (*) 7.5 15
Hydroxypropyl emthylcellulose 34 34
Magnesium stearate 0.8 0.8
Silica sol 0.32 0.32
Final weight 160 160
8 hours dissolved active component (%) 73 84
(*) amount of maltodextrin equals 6 to 12% of granulated material (active component+dicalcium phosphate dihydrate+maltodextrin) amount.
Fig. 3 represents the kinetic curve of dissolution of two preparations adopting
The amount of maltodextrin, when hydroxypropyl emthylcellulose weight was stablized, influence discharged greater than the active component in 4 little periods.Solubility curve is by the increment linearisation of maltodextrin.
Embodiment 2:
Embodiment 2 shows that hydroxypropyl cellulose is to the release in vitro effect of kinetics.The consumption of hydroxypropyl emthylcellulose is 26 to 42mg.Thereby constitute sheet heavy 16 to 26%.
Table 2: the unit preparation (every of mg) of tablet
Batch
Component LP3 LP4
Gliclazide 30 30
Dicalcium phosphate dihydrate 79.87 94.91
Maltodextrin (*) 7.01 7.97
Hydroxypropyl emthylcellulose 42 26
Magnesium stearate 0.8 0.8
Silica sol 0.32 0.32
Final weight 160 160
4 hours dissolved active component (%) 35 52
(*) amount of maltodextrin equals 6% of granulated material (active component+dicalcium phosphate dihydrate+maltodextrin).
Fig. 4 represents the kinetic curve of dissolution of two preparations adopting:
The hydroxypropyl emthylcellulose amount influences the release of active component strongly in the hydrophilic skeleton.
Embodiment 3:
Embodiment 3 shows that the rank of the hydroxypropyl emthylcellulose that adopts is to the release in vitro effect of kinetics.In each batch, the gross weight of hydroxypropyl cellulose is stable, and the relative quantity of the hydroxypropyl emthylcellulose of every kind of different viscosities changes, thereby, slowly dissolved batch (LP5) and quick dissolving batch (LP7), batch (LP6) compares with contrast.
Table 3: the unit preparation (mg) of tablet
Batch
Component LP5 LP6 LP7
Gliclazide 30 30 30
Dicalcium phosphate dihydrate 83.64 83.64 83.64
Maltodextrin (*) 11.24 11.24 11.24
Hydroxypropyl emthylcellulose 4000cP 24 16 8
Hydroxypropyl emthylcellulose 100cP 10 18 26
Magnesium stearate 0.8 0.8 0.8
Silica sol 0.32 0.32 0.32
Final weight 160 160 160
4 hours dissolved active component (%) 33 46 58
(*) amount of maltodextrin equals 9% of granulated material (active component+dicalcium phosphate dihydrate+maltodextrin).
Fig. 5 represents the kinetic curve of dissolution of three kinds of preparations adopting:
Curve clearly illustrates the consumption of hydroxypropyl emthylcellulose in the hydrophilic skeleton not only, and the rank of the hydroxypropyl emthylcellulose that adopts influences the dissolution kinetics of active component.
After the single-dose of LP6 sheet, measure the blood plasma kinetics of gliclazide in 12 receptors.Fig. 6 has provided mean plasma concentration.
This curve display matrix type solubility curve (active component discharges continuously) has single chamber blood plasma kinetics.
Embodiment 4:
Embodiment 4 shows that the release in vitro kinetics of 60mg dosage sheets is similar to 30mg dosage sheet (LP6 criticizes) in the hydroxypropyl emthylcellulose that contains same dosage and the maltodextrin matrix tablet,
Table 4: the unit preparation (every of mg) of tablet
LP8 criticizes
Component
Gliclazide
60
Dicalcium phosphate dihydrate 53.64
Maltodextrin 11.24
Hydroxypropyl emthylcellulose 34
Colloidal silica anhydrous 0.32
Magnesium stearate 0.8
Final weight 160mg
4 hours dissolved active component (%) 45

Claims (15)

1. slow release gliclazide matrix tablet, it is characterized in that it comprises the combination of at least a cellulosic polymer chemical compound and glucose syrup, the percent of cellulosic polymer chemical compound is 10 to 40% of described gross weight, the percent of glucose syrup is 2 to 20% of described gross weight, and this combination can be controlled the prolongation release of gliclazide and make that the dissolving release dynamics of gliclazide is insensitive to the change of pH.
2. according to the gliclazide matrix tablet of claim 1, it is characterized in that the cellulosic polymer chemical compound comprises at least a hydroxypropyl emthylcellulose.
3. according to the gliclazide matrix tablet of claim 1 or 2, it is characterized in that the cellulosic polymer chemical compound comprises the mixture of two kinds of different viscosities hydroxypropyl emthylcelluloses.
4. according to the gliclazide matrix tablet of claim 3, it is characterized in that the cellulosic polymer chemical compound comprises the mixture of the hydroxypropyl emthylcellulose of the hydroxypropyl emthylcellulose of 4 pascal second viscosity and 0.1 pascal second viscosity.
5. according to the gliclazide matrix tablet of claim 1, it is characterized in that glucose syrup is a maltodextrin.
6. according to the gliclazide matrix tablet of claim 1, the percent that it is characterized in that the cellulosic polymer chemical compound is 16 to 26% of described gross weight.
7. according to the gliclazide matrix tablet of claim 1, the percent that it is characterized in that glucose syrup is 4 to 10% of described gross weight.
8. according to the gliclazide matrix tablet of claim 1, it is characterized in that dicalcium phosphate dihydrate is used as diluent.
9. according to the gliclazide matrix tablet of claim 8, the percent that it is characterized in that diluent is 35 to 75% of described gross weight.
10. according to the gliclazide matrix tablet of claim 8, the percent that it is characterized in that diluent is 45 to 60% of described gross weight.
11. according to the gliclazide matrix tablet of claim 1, the amount that it is characterized in that gliclazide is 12 to 40% of a described gross weight.
12., it is characterized in that its total amount that contains gliclazide is 30mg according to the gliclazide matrix tablet of claim 1 or 11.
13., it is characterized in that its total amount that contains gliclazide is 60mg according to the gliclazide matrix tablet of claim 1 or 11.
14. according to the preparation method of the gliclazide matrix tablet of claim 1, it is characterized in that its adopts wet granulation technique and direct compression technology, comprise the following steps:
Steps A:
The mixture of gliclazide, maltodextrin and dicalcium phosphate dihydrate, with the pure water wet mix, the moist wood of gained is then granulated, dry and classification subsequently, obtains having the granule that can well fill the physical features of quick tablet machine mould;
Step B:
The granulate mixture that steps A obtains mixes with hydroxypropyl emthylcellulose;
Step C:
Lubricate the mixture that step B obtains with silica sol and magnesium stearate;
Step D:
The lubrication mixture that adopts rotary tablet machine tabletting step C to obtain, with obtain to measure by the diameter crushing, have 6 * 10 -5Newton to 1.0 * 10 -4The sheet of newton's hardness.
15. the purposes of gliclazide matrix tablet in the medicine of preparation treatment diabetes according to claim 1.
CNB998159603A 1999-02-01 1999-10-15 Core tablet for controlled release of gliclazide after oral administration Expired - Lifetime CN1160061C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/01082 1999-02-01
FR9901082A FR2788981B1 (en) 1999-02-01 1999-02-01 MATRIX TABLET FOR THE EXTENDED RELEASE OF GLICLAZIDE AFTER ORAL ADMINISTRATION

Publications (2)

Publication Number Publication Date
CN1342068A CN1342068A (en) 2002-03-27
CN1160061C true CN1160061C (en) 2004-08-04

Family

ID=9541429

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998159603A Expired - Lifetime CN1160061C (en) 1999-02-01 1999-10-15 Core tablet for controlled release of gliclazide after oral administration

Country Status (37)

Country Link
US (1) US6733782B1 (en)
EP (1) EP1148871B1 (en)
JP (2) JP4716465B2 (en)
KR (1) KR100491600B1 (en)
CN (1) CN1160061C (en)
AP (1) AP1243A (en)
AT (1) ATE296621T1 (en)
AU (1) AU764516B2 (en)
BR (1) BR9917012A (en)
CA (1) CA2273420C (en)
CZ (1) CZ298196B6 (en)
DE (1) DE69925639T2 (en)
DK (1) DK1148871T3 (en)
EA (1) EA002625B1 (en)
EE (1) EE05024B1 (en)
ES (1) ES2241323T3 (en)
FR (1) FR2788981B1 (en)
GE (1) GEP20053501B (en)
HK (1) HK1043049A1 (en)
HR (1) HRP20010632B1 (en)
HU (1) HU225693B1 (en)
ID (1) ID30225A (en)
IL (2) IL144246A0 (en)
ME (1) ME00436B (en)
NO (1) NO329951B1 (en)
NZ (1) NZ512878A (en)
OA (1) OA11756A (en)
PL (1) PL194505B1 (en)
PT (1) PT1148871E (en)
RS (1) RS50121B (en)
SA (1) SA00210446B1 (en)
SK (1) SK285209B6 (en)
TR (1) TR200102002T2 (en)
UA (1) UA68414C2 (en)
WO (1) WO2000018373A1 (en)
YU (1) YU53101A (en)
ZA (1) ZA200106305B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
SE0200539D0 (en) * 2002-02-25 2002-02-25 Metcon Medicin Ab Granulation process and starch granulate
CN100391459C (en) * 2003-05-26 2008-06-04 沈阳药科大学 Doxazosin mesilate slow releasing preparation
CN1294908C (en) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 Oral gliclazide sustained release formulation
AU2004318976B2 (en) * 2004-04-29 2009-04-09 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
CN100413491C (en) * 2004-06-14 2008-08-27 北京德众万全药物技术开发有限公司 Sustained release preparation of solution resistant medicine
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
EP1946780B1 (en) 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
TR200704897A1 (en) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Glyclazide formulations providing extended release @
TR200708938A2 (en) * 2007-12-26 2008-11-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Glyclazide tablet for extended release
ITFI20080016A1 (en) * 2008-02-05 2009-08-06 Valpharma Sa PHARMACEUTICAL FORMULATIONS ORAL CONTAINING GLYCLAZIDE.
FR2928836B1 (en) * 2008-03-21 2011-08-26 Servier Lab SECURE GALENIC FORM FOR MODIFIED RELEASE OF THE ACTIVE INGREDIENT
WO2009140279A2 (en) * 2008-05-12 2009-11-19 Concert Pharmaceuticals, Inc. Sulfonyl urea compounds
EP2181705A1 (en) 2008-10-31 2010-05-05 Disphar International B.V. Sustained-release formulation of gliclazide
NZ594648A (en) * 2009-03-03 2013-12-20 Xenoport Inc Sustained release oral dosage forms of an r-baclofen prodrug
JP5669837B2 (en) 2010-06-16 2015-02-18 帝人ファーマ株式会社 Controlled release nucleated tablets
EP2468268B1 (en) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Combination composition of vildagliptin and gliclazide
TR201107482A1 (en) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. The bilayer combination composition of vildagliptin and glyclazide.
TR201103946A1 (en) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Glyclazide formulations for controlled release.
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
US20150031737A1 (en) * 2012-02-24 2015-01-29 Ranbaxy Laboratories Limited Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2014128116A1 (en) * 2013-02-19 2014-08-28 Sanovel Ilac Sanayi Ve Ticaret A.S. A production process for gliclazide formulations
ITFI20130184A1 (en) * 2013-08-01 2015-02-02 Valpharma Internat S P A PHARMACEUTICAL FORMULATION OF GLYCLAZIDE WITH MODIFIED RELEASE, ADMINISTRABLE BY ORAL ROUTE, AND ITS PRODUCTION METHOD.
ITMI20132065A1 (en) * 2013-12-11 2015-06-12 Farmatron Ltd THERAPEUTIC RELEASE SYSTEMS MODIFIED FOR ORAL CURCUMIN ADMINISTRATION IN THE TREATMENT OF INTESTINAL DISEASES
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
WO2016042568A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of gliclazide
CN111329841B (en) * 2020-03-04 2021-11-19 山东鲁抗医药集团赛特有限责任公司 Gliclazide sustained release tablet and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1449404A (en) * 1973-03-30 1976-09-15 Science Union & Cie N-arylsulphonyl urea derivatives
US4056623A (en) * 1975-03-05 1977-11-01 Science Union Et Cie, Societe Francaise De Recherche Medicale Methods of treating animals suffering from hyperlipidemia using certain N-phenyl sulphonyl-N'-(3-azabicycloalkyl) ureas
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1246188B (en) * 1990-07-27 1994-11-16 Resa Farma PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING INCREASED SPEED OF DISSOLUTION OF THE ACTIVE SUBSTANCE AND COMPOSITIONS OBTAINED.
DE4336159A1 (en) * 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Highly effective forms of preparation of sulfonylureas that release the active ingredient quickly or in a controlled manner and processes for their preparation
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.

Also Published As

Publication number Publication date
PT1148871E (en) 2005-08-31
SK285209B6 (en) 2006-08-03
RS50121B (en) 2009-03-25
NO20013757D0 (en) 2001-07-31
JP2002525310A (en) 2002-08-13
WO2000018373A1 (en) 2000-04-06
YU53101A (en) 2004-05-12
GEP20053501B (en) 2005-05-10
FR2788981B1 (en) 2002-05-17
HRP20010632B1 (en) 2006-02-28
EE200100398A (en) 2002-10-15
NO329951B1 (en) 2011-01-31
DE69925639T2 (en) 2006-04-27
ME00436B (en) 2011-10-10
HRP20010632A2 (en) 2005-02-28
CZ20012661A3 (en) 2001-11-14
TR200102002T2 (en) 2002-01-21
PL194505B1 (en) 2007-06-29
FR2788981A1 (en) 2000-08-04
US6733782B1 (en) 2004-05-11
UA68414C2 (en) 2004-08-16
CA2273420A1 (en) 2000-08-01
CA2273420C (en) 2002-07-09
ES2241323T3 (en) 2005-10-16
BR9917012A (en) 2002-04-16
ID30225A (en) 2001-11-15
OA11756A (en) 2005-07-19
EA002625B1 (en) 2002-06-27
PL356707A1 (en) 2004-06-28
HUP0105365A3 (en) 2002-11-28
ZA200106305B (en) 2002-07-31
AU6098299A (en) 2000-04-17
DK1148871T3 (en) 2005-09-19
KR100491600B1 (en) 2005-05-27
EE05024B1 (en) 2008-06-16
KR20010093307A (en) 2001-10-27
HK1043049A1 (en) 2002-09-06
JP2008179649A (en) 2008-08-07
AU764516B2 (en) 2003-08-21
EA200100827A1 (en) 2002-02-28
CZ298196B6 (en) 2007-07-18
SK10952001A3 (en) 2001-12-03
HU225693B1 (en) 2007-06-28
EP1148871B1 (en) 2005-06-01
AP2001002212A0 (en) 2001-09-30
ATE296621T1 (en) 2005-06-15
SA00210446B1 (en) 2006-10-11
IL144246A0 (en) 2002-05-23
HUP0105365A2 (en) 2002-04-29
EP1148871A1 (en) 2001-10-31
IL144246A (en) 2006-12-10
JP4716465B2 (en) 2011-07-06
DE69925639D1 (en) 2005-07-07
NZ512878A (en) 2002-05-31
NO20013757L (en) 2001-08-09
AP1243A (en) 2004-02-02
CN1342068A (en) 2002-03-27

Similar Documents

Publication Publication Date Title
CN1160061C (en) Core tablet for controlled release of gliclazide after oral administration
US20090238870A1 (en) Dividable galenical form allowing modified release of the active ingredient
CN1245158C (en) Tabletted prepn.
HU218658B (en) Verapamyl compositions of controlled dissolution and process for producing them
EP1827453A1 (en) Sulfonylurea compositions and a process for its preparation
CN1649603A (en) Aqueous compositions containing metronidazole
CN1116029C (en) Matrix table allowing prolonged release of sodium salt of tianeptine after administration by oral route
CN1921839A (en) Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof
RU2449778C1 (en) Diuretic composition with delayed release
CN1476898A (en) Compound skeleton tablet capable of prolonging release after oral administrationi for curing common cold
CN1839801A (en) Insoluble pharmaceutical slow release preparation
WO2003043607A1 (en) A pharmaceutical composition for controlled release of a beta-lactam antibiotic
CN1131023C (en) Sustained release excipient
JP2002145780A5 (en)
US11717486B2 (en) Highly stable formulations of thyroid hormone in soft capsules
CN1259909C (en) Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
CN1275597C (en) System with extensible released drug containing extract of hawkthom leaves
CN1836667A (en) Eye drop
CN1215591A (en) Chroman derivative-containing ophthalmic solution

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
CI01 Publication of corrected invention patent application

Correction item: Applicant

Correct: Laboratoires Therwill

False: Adir Et Compagnie

Number: 13

Page: 137

Volume: 18

CI02 Correction of invention patent application

Correction item: Applicant

Correct: Laboratoires Therwill

False: Adir Et Compagnie

Number: 13

Page: The title page

Volume: 18

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ADIR ET CO. TO: SERVIER LAB

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1043049

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: FRENCH SERVIER PHARMACEUTICAL FACTORY

Free format text: FORMER NAME: SERVIER PHARMACEUTICAL COMPANY

CP01 Change in the name or title of a patent holder

Address after: Kolb tile

Patentee after: LES LABORATOIRES SERVIER

Address before: Kolb tile

Patentee before: Pharmaceutical laboratories

CX01 Expiry of patent term

Granted publication date: 20040804

CX01 Expiry of patent term